You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 4,704,383

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,704,383

Title:	Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
Abstract:	Tetracyclines having substantially no effective antibiotic or antibacterial activity and possessing anti-collagen-destructive enzyme activity or anti-collagenase activity and compositions containing the same have been found useful as anti-collagenolytic agents. Such tetracyclines and compositions containing the same are useful in the treatment of periodontal diseases, corneal ulcers, bone deficiency disorders, rheumatoid arthritis diseases characterized by excessive collagen destruction. A special aspect of this invention involves the incorporation of such tetracyclines in animal feed compositions for improved animal nutrition, such as may be evidenced by increased weight gain.
Inventor(s):	McNamara; Thomas F. (Port Jefferson, NY), Ramamurthy; Nungavaram S. (Smithtown, NY), Golub; Lorne M. (Smithtown, NY)
Assignee:	The Research Foundation of State University of New York (Albany, NY)
Application Number:	06/699,048
Patent Claims:	1. A method for treating humans or animals suffering from a condition or disease characterized by excessive collagen destruction due to collagen-destructive enzymes which comprises administering to said human or animal an effective anti-collagenase amount of tetracycline having substantially no effective antibiotic or antibacterial activity. 2. A method in accordance with claim 1 wherein said tetracycline is dedimethylaminotetracycline. 3. A method in accordance with claim 1 wherein said excessive collagen destruction is evidenced by ulceration of the cornea. 4. A method in accordance with claim 1 wherein said excessive collagen destruction is evidenced by periodontal disease. 5. A method in accordance with claim 1 wherein said excessive collagen destruction is evidenced by rheumatoid arthritis.

Details for Patent 4,704,383

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2004-11-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.